Tesamorelin Results: Week-by-Week Timeline (2026)

Months 2-3: Measurable Body Composition Changes

This is where data starts showing up in measurements, not just blood work. The clinical trials begin detecting meaningful differences from placebo during this window.

What's happening internally:

Visceral fat reduction becomes CT-measurable — the pivotal Phase III trial showed significant visceral adipose tissue reduction emerging during this period (Falutz et al., 2007)

Lean body mass begins increasing measurably — pooled Phase III data confirmed significant lean tissue accrual alongside fat reduction (Falutz et al., 2010)

Liver enzymes (ALT) begin improving in those with elevated baseline levels (Fourman et al., 2017)

Intramuscular fat starts decreasing while muscle cross-sectional area and density increase (Stanley et al., 2019)

What users and trial subjects commonly report:

Waist circumference reduction — the first metric most people can track at home

Clothes fitting differently around the midsection, even if scale weight has not changed significantly

Improved workout recovery and potentially increased training capacity

Better body composition visible in the mirror — less abdominal bloat, more midsection definition

Metabolic markers improving on blood work (triglycerides, cholesterol ratios beginning to shift)

The recomposition paradox: Tesamorelin at this stage is doing something unusual — reducing visceral fat while adding lean tissue simultaneously. Your scale weight may not change dramatically because fat loss and muscle gain offset each other. This is not a failure — it is the desired outcome. Waist circumference, progress photos, and body composition scans tell the real story. The scale lies.

Recommended blood work at 8-12 weeks:

IGF-1 (should be elevated but within physiological range)

Fasting glucose and HbA1c (monitor for GH-mediated insulin effects)

Liver enzymes — ALT, AST (should be stable or improving)

Lipid panel (triglycerides and cholesterol ratios trending favorably)

Months 4-6: Peak Clinical Effect

The Phase III trials measured their primary endpoints at 26 weeks (6 months). This is where tesamorelin delivers its maximum documented benefit — and where the strongest data exists.

What the clinical data shows:

~15-18% reduction in visceral adipose tissue by CT scan at 26 weeks versus placebo (Falutz et al., 2007)

Significant improvements in trunk fat, waist circumference, and waist-to-hip ratio

Improved body image scores — patients reported meaningful improvements in belly appearance distress and physician-rated belly profile

Sustained IGF-1 elevation within normal physiological range

Metabolic improvements in triglycerides, cholesterol ratios, and inflammatory markers correlated with the degree of visceral fat loss (Stanley et al., 2012)

In patients with NAFLD, liver fat reduction and prevention of fibrosis progression documented at 12 months of continued treatment (Stanley et al., 2019)

Significant visible reduction in abdominal size — before/after comparisons become obvious at this stage

Improved body composition that others will notice

Sustained energy, sleep, and recovery improvements

Blood work showing comprehensive metabolic improvement across lipid and hepatic markers

For those who had elevated liver enzymes at baseline, measurably improved hepatic markers

Diminishing returns: The rate of visceral fat loss is highest during the first 26 weeks. Extension studies to 52 weeks showed maintained benefits but not dramatically accelerated losses beyond the 6-month mark. The biggest gains happen in this 4-6 month window. After 6 months, the trial data describe maintenance of accrued gains rather than rapid new improvements.

Results summary by goal:

Visceral fat loss

Weeks 4-8

Weeks 12-16

26 weeks

Lean body mass

Weeks 4-6

Weeks 8-12

26+ weeks

Metabolic markers

Weeks 16-26

Liver fat reduction

52 weeks

Sleep and recovery

Days 3-7

Weeks 2-4

Factors That Affect Results

Not everyone responds identically. These variables influence the specific timeline and magnitude of response.

Starting visceral fat level

Patients with higher baseline visceral adipose tissue in clinical trials showed greater absolute reductions. Individuals carrying significant visceral fat (waist-to-hip ratio above 0.9 for men, 0.85 for women) have more to lose and tend to show more dramatic changes. Conversely, in already-lean individuals the visceral fat reduction is less noticeable.

Dose consistency

Phase III results came from daily dosing at 2 mg without interruption for 26 weeks. Missed doses, inconsistent timing, or underdosing slow the timeline. Tesamorelin works through sustained GH elevation — every gap in dosing is a gap in the lipolytic signal to visceral fat cells.

Diet and training

Clinical trials did not mandate specific diet or exercise protocols, yet still showed significant results. Adding resistance training capitalizes on the GH-mediated protein synthesis boost and likely amplifies lean mass gains beyond what the trials demonstrated. A moderate caloric approach (not aggressive restriction) supports the recomposition effect — fuel is required for both fat mobilization and muscle building.

Age and baseline GH status

Older individuals with lower baseline GH production may see more dramatic GH restoration effects. Younger individuals with already-robust GH output may see less relative improvement, since tesamorelin works by stimulating endogenous GH rather than replacing it.

Cycling versus continuous use

The FDA-approved protocol is continuous daily dosing. In the pooled Phase 3 program, tesamorelin was dosed every day for 52 continuous weeks: IGF-1 reached its elevated plateau by week 26 and was held at that level through week 52, and the trials documented no tachyphylaxis (no loss of response over time) on continuous daily dosing, with visceral-fat reduction sustained across the full year (52-week extension, Falutz et al., 2010). Community off-label protocols often cycle 8-16 weeks on, 4-8 weeks off, typically described in the context of cost management and letting IGF-1 normalize between blocks. Use our tesamorelin cycle cost calculator to compare spending across different cycle lengths. Cycling means visceral fat may partially rebound during off periods, while continuous use mirrors the FDA-approved protocol and carries the strongest trial evidence for a sustained, non-attenuating response. See Do GH Peptides Desensitize the Pituitary? for how this compares across GH secretagogues.

When to Adjust the Protocol

Signs it is working (stay the course):

IGF-1 rising on blood work at 4-6 weeks (within physiological range)

Waist circumference decreasing by month 2-3

Sleep and recovery subjectively improving within the first month

Liver enzymes stable or improving (if previously elevated)

Clothes fitting differently around the midsection by week 8-12

Signs to reassess:

No IGF-1 increase at week 4 — suggests possible dosing issue, degraded product, or poor absorption. Verify the source, check reconstitution and storage, and confirm injection technique

No waist circumference change at week 12-16 — complete non-response at this timepoint warrants evaluation. Some individuals may need the full 26 weeks, but total non-response deserves investigation

Fasting glucose rising significantly — GH can impair insulin sensitivity in some individuals. This requires medical attention and possible dose adjustment

IGF-1 above reference range — dose reduction or discontinuation may be needed. Supraphysiological IGF-1 carries long-term risks

What happens after stopping:

Phase III trials clearly showed visceral fat regain after tesamorelin discontinuation. The benefits do not persist indefinitely after stopping. GH and IGF-1 return to baseline levels, and the lipolytic stimulus to visceral fat cells ceases. This is why many off-label protocols use extended cycles or continuous lower-dose maintenance rather than short bursts. The data supports sustained use for sustained results.